According to IMARC Group, the global Cell and Gene Therapy Market Size reached USD 24.8 Billion in 2025 and is projected to reach USD 81.5 Billion by 2034, exhibiting a robust CAGR of 13.71% during 2026–2034. The Cell and Gene Therapy Market Share is being driven by accelerating clinical approvals, increasing public and private investments in biotech research, growing awareness among healthcare providers, and a strong pipeline of novel therapies targeting oncology, rare genetic disorders, cardiovascular conditions, and neurological diseases.

What Is Cell and Gene Therapy?

Cell and gene therapy represents two interrelated yet distinct cutting-edge medical disciplines that harness the power of human biology to treat disease at its root cause. In cell therapy, living cells—often genetically modified—are transplanted or engineered to replace or repair damaged tissues and enhance immune responses. In gene therapy, genetic material is introduced, modified, or removed within a patient’s cells to correct faulty genes responsible for disease.

Together, these therapies are revolutionizing treatment paradigms across multiple medical fields. Key applications include:

• Engineering CAR-T cells and natural killer (NK) cells for targeted cancer immunotherapy across multiple tumor types
• Correcting single-gene defects responsible for hereditary conditions such as sickle cell disease, hemophilia, and muscular dystrophy
• Regenerating damaged cardiac tissue using stem cell-based approaches in cardiovascular disease management
• Delivering gene-editing tools directly into the body (in-vivo) or modifying cells outside the body before reinfusion (ex-vivo)
• Developing next-generation therapies for neurological conditions including Parkinson’s disease and spinal muscular atrophy
• Leveraging viral vectors and nanoparticle delivery systems for precise and efficient therapeutic gene transfer

Cell and Gene Therapy Market Trends indicate a growing shift toward personalized, disease-modifying interventions that offer long-lasting and potentially curative outcomes for patients with limited treatment alternatives.

Global Cell and Gene Therapy Market Overview & Key Statistics

Key Cell and Gene Therapy Market Trends & Drivers in 2026

Several converging factors are accelerating growth across the global Cell and Gene Therapy Market:

Advancements in Biotechnology and Genetic Research

Significant progress in gene-editing platforms, particularly CRISPR-Cas9 and viral vector technologies, has unlocked the ability to precisely modify genes and engineer therapeutic cells. These breakthroughs have enabled treatments for previously incurable genetic disorders and are attracting substantial investments from both the public and private sectors. As biotechnological capabilities continue to advance, the pipeline of innovative cell and gene therapies continues to expand rapidly.

Rising Prevalence of Chronic Diseases and Aging Populations

The growing global burden of chronic conditions including cancer, neurodegenerative diseases, and cardiovascular disorders is a fundamental driver of Cell and Gene Therapy Market growth. Traditional treatment options frequently fall short for patients with complex or rare diseases, creating significant unmet medical need. Cell and gene therapies offer the potential to address these gaps with personalized, genetically targeted interventions tailored to individual patient profiles.

Supportive Regulatory Frameworks and Streamlined Approval Processes

Regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval pathways—such as Breakthrough Therapy Designation, Accelerated Approval, and the Regenerative Medicine Advanced Therapy (RMAT) designation—specifically designed to fast-track promising cell and gene therapies to patients. This supportive environment has fostered greater investor confidence and significantly accelerated the commercialization of approved therapies.

Strategic Collaborations Across the Healthcare and Biotech Ecosystem

Increasing collaborations between pharmaceutical companies, biotechnology firms, academic research institutions, and hospitals are accelerating the development and scale-up of novel therapies. These strategic partnerships enable knowledge-sharing, technology transfer, access to clinical expertise, and shared infrastructure for manufacturing—all of which are critical to advancing the Cell and Gene Therapy Market.

Burgeoning Investments in Manufacturing Infrastructure

As cell and gene therapies move from early-stage clinical trials to commercial-scale production, significant investments are being directed toward building advanced manufacturing capabilities. Improvements in bioprocessing technologies, cell culture systems, and quality control frameworks are improving scalability, reproducibility, and the commercial viability of these complex therapies.

Growing Awareness and Acceptance Among Patients and Healthcare Providers

Rising awareness about the clinical benefits of cell and gene therapies—particularly for life-threatening and rare conditions—is driving increased acceptance among healthcare professionals and patients. As more therapies gain regulatory approval and clinical evidence accumulates, adoption rates are expected to accelerate meaningfully across all major global markets.

Key Cell and Gene Therapy Market Segmentation

By Therapy Type

Cell Therapy – Includes stem cell-based therapies (pluripotent stem cells, cancer stem cells, adult stem cells) and non-stem cell therapies (T cells, natural killer cells, and others). Stem cell therapy is fueled by regenerative medicine advances and its ability to repair or replace damaged tissues and organs.

Gene Therapy – Involves the precise modification of genetic material using tools such as CRISPR-Cas9 to correct or replace defective genes. Gene therapy holds the potential for curative outcomes in hereditary disorders and has attracted growing clinical success and investor interest.

By Indication

• Oncology Disorder – Largest Segment | Cancer’s high global prevalence and the effectiveness of CAR-T and other immune cell therapies drive dominance in this indication
• Cardiovascular Disease | Cell-based approaches targeting cardiac tissue repair and regeneration
• Genetic Disorder | Therapies for hereditary conditions such as hemophilia, Duchenne muscular dystrophy, and sickle cell disease
• Infectious Disease | Genetically modified cell therapies targeting HIV and other persistent viral infections
• Neurological Disorder | Emerging therapies for Parkinson’s, ALS, and spinal muscular atrophy
• Others | A range of rare and complex conditions being targeted by novel pipeline therapies

By Delivery Mode

• In-Vivo | Therapeutic genes or cells are delivered directly into the patient’s body using viral vectors or nanoparticles, enabling targeted tissue delivery while minimizing systemic side effects
• Ex-Vivo | Cells are extracted from the patient, genetically modified outside the body using gene-editing tools, and reinfused. Advances in bioprocessing and genetic engineering have improved the scalability and therapeutic quality of ex-vivo approaches

By End User

• Hospitals – Largest Segment | As primary centers for specialized patient care and clinical trial implementation, hospitals account for the largest share of market demand
• Cancer Care Centers | Specialized oncology centers increasingly integrating CAR-T and other advanced immunotherapies
• Pharmaceutical & Biotechnology Companies | Major developers and manufacturers of cell and gene therapy products
• Others | Academic research institutions, regenerative medicine centers, and outpatient specialty clinics

Regional Cell and Gene Therapy Market Analysis

Leading Companies in the Cell and Gene Therapy Industry

The global Cell and Gene Therapy Market features a competitive landscape of pharmaceutical giants, specialized biotechnology companies, and innovative research-driven startups. Key players covered in the IMARC report include:

• Amgen Inc.

• Biogen

• Bluebird bio, Inc.

• Bristol-Myers Squibb

• Gilead Sciences

• Kolon TissueGene Inc.

• Orchard Therapeutics plc

• Pfizer Inc.

• Renova Therapeutics

• Spark Therapeutics, Inc.

• And more as detailed in the full IMARC report

The IMARC report covers competitive analysis including market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant.

Recent Developments in the Cell and Gene Therapy Market

• In March 2023, Spark Therapeutics announced work on its USD 575 million gene therapy innovation center in Philadelphia, signaling major long-term capacity expansion in the sector.

• In August 2023, Kolon TissueGene raised USD 29.6 million to advance its cell and gene therapy pipeline, initially targeting osteoarthritis of the knee.

• In June 2023, Amgen announced that the FDA approved a supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL).

About the Author

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Healthcare, Chemicals & Materials, Food & Beverages, Energy, and more.

Media & Sales Contact

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Health-Fitness/83509-Cell-and-Gene-Therapy-Market-Size-Trends-Growth-and-Forecast-2026-2034.html